April 30th – May 4th, 2018
Seaport World Trade Center
Boston, MA
Please stop by our Booth 601!

Oncology Stream
Luncheon Presentation #1
Time: 12:50 PM, April 30th, 2018
Title: In Vivo Platform for Generation Human “Heavy Chain Only” Antibodies for Drug Discovery
Presenter: Frank Grosveld, Ph.D., Professor of Cell Biology, Erasmus MC, and Founder of Harbour Antibodies BV

Profile: Dr. Frank Grosveld founded Harbour Antibodies in 2006 at Erasmus MC, Rotterdam, the Netherlands. He and his team were responsible for the development of two strains of transgenic mice for generating human therapeutic antibodies: (1) H2L2 – mice that generate antibodies comprised of two heavy chains and two light chains with fully human variable regions; and (2) HCAb – mice that generate novel“heavy chain only” antibodies. The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties.

Dr. Grosveld studied biochemistry at the University of Amsterdam and obtained his PhD from McGill University. He is a Professor of Cell Biology at the Erasmus Medical Center. His group has filed considerable number of patents in the area of Immunology and Genomics and has closely collaborated with industrial partners. Dr. Grosveld is a fellow of the Royal Society and a member of the Dutch Academy of Science, and a member of the Scientific Advisory Board for Harbour BioMed.

More information on PEGS-Boston Conference:
http://www.pegsummit.com

Harbour BioMed Contact:
Timothy Miller
Harbour Antibodies
90 Bridge Street, Suite 100
Newton, MA 02478, USA
timothy.miller@harbourbiomed.com